Runx transcription factors regulate viral growth, hematopoiesis, bone formation, angiogenesis, and gastric epithelial development through specific DNA-binding motifs on target gene promoters. Vascular endothelial cells (ECs) express RUNX genes that are activated by angiogenic factors. The RUNX2 gene also activates the vascular endothelial growth factor promoter. Alternatively spliced forms of RUNX genes have been described, but their functions in angiogenesis have not been elucidated. In this study, expression of a novel alternatively spliced variant of RUNX2 (RUNX2D8), lacking the region encoded by exon 8, was detected in aortic tissue undergoing angiogenesis in vitro and in ECs. Expression of RUNX2 and RUNX2D8 increased in vascular sprouts concomitant with expression of cellular proteases and cytokines known to mediate angiogenesis. RUNX2 DNA-binding activity was expressed in proliferating but not quiescent ECs. Ectopic expression of RUNX2 in ECs increased cell sprouting, cell proliferation, DNA synthesis, and phosphorylation of phosphorylated retinoblastoma relative to control transfectants while RUNX2, but not RUNX2D8 transfectants, acquired resistance to growth inhibition by transforming growth factor (TGFb 1 ). Furthermore, RUNX2D8-transfected cells were more sensitive to TGFb 1 -induced apoptosis than RUNX2 transfectants. Consistent with these data, the RUNX2 gene was a strong repressor of the promoter of the cyclin-dependent kinase inhibitor, p21 CIP1 , while RUNX2D8 was a competitive inhibitor of RUNX2 and exhibited weak repression activity. These results support the hypothesis that ECs regulate growth and apoptosis, in part, by alternative splicing events in the RUNX2 transcription factor to affect the TGFb 1 signaling pathway. The exon 8 domain of RUNX2 may contribute to the strong repression activity of RUNX2 for some target gene promoters.
Introduction
Neovascularization is an essential developmental process that is activated under pathological conditions and controlled by the expression of growth-promoting and growth-suppressing angiogenesis factors (Folkman, 1995; Beck and D'Amore, 1997; Ferrara, 2000; Kerbel, 2000; Li, 2000) . During the initial activation stage, tumor or epithelial cells secrete angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietins that alter cell cycle kinetics and stimulate endothelial cell (EC) proliferation or migration (Hanahan, 1997; Maisonpierre et al., 1997; Carmeliet and Collen, 2000) . In later stages, tube formation and vessel maturation lead to vessel remodeling and apoptosis, which are regulated by transforming growth factor (TGFb 1 ) and mesenchymal cells in the absence of EC proliferation (Pepper et al., 1990; Beck and D'Amore, 1997; Taipale and Keski-Oja, 1997) . This complex process of gene expression is regulated by a variety of transcription factors whose functions in angiogenesis have been deduced from targeted gene disruption studies in vivo or in cultured cells (Sato, 2000) .
The Runx genes are a conserved family of DNAbinding proteins containing a unique Runt homology domain (RHD) originally described in Drosophila (Ito, 1999) . The RUNX proteins are members of the Ig-loop DNA-binding family of proteins that include Stat1, p53, and nuclear factor-kB (NF-kB) (Bravo et al., 2001) . Runx proteins are phosphorylated (Selvamurugan et al., 2000; Xiao et al., 2000) and associate with the corebinding factor-b (Cbfb) in the nucleus to bind a specific nucleotide sequence. Several key observations support a role for Runx genes in angiogenesis including the finding that mice in which either the Runx1 or Runx2 genes have been disrupted die in utero or soon after birth with vascular abnormalities Lund and Van Lohuizen, 2002 ). Runx1-negative mice fail to recruit hematopoietic stem cells for angiogenesis and exhibit defective vessel formation in the pericardium and head (Takakura et al., 2000) . In Runx2-deficient mice, there is no vascular or mesenchymal cell invasion in cartilage, no evidence of VEGF expression in hypertrophic chondrocytes, and consequently no bone formation (Komori et al., 1997; Otto et al., 1997; Zelzer et al., 2001) . The absence of VEGF may be a direct consequence of reduced Runx2 binding to the VEGF promoter (Zelzer et al., 2001) . Conversely, VEGF, along with several angiogenic factors including FGF-1 and insulin-like growth factor-1 (IGF-1), stimulate RUNX2 expression and migration of EC in vitro and in vivo (Namba et al., 2000; Sun et al., 2001) . Reports of RUNX1 expression in human vascular EC and brain tumor cells in vivo also indicate that Runx genes are upregulated in highly vascularized malignant tumors (Perry et al., 2002) .
RUNX2 contains two domains not shared by other Runx family proteins: a QA-rich domain important in regulating transcription and a domain of unknown function encoded in exon 8 (Westendorf and Hiebert, 1999) . Alternatively spliced Runx2 isoforms have been reported (Stewart et al., 1997) , including alternatively spliced exon 8 , which exhibited reduced transactivation relative to RUNX2 (Geoffroy et al., 1998) , as well as isoforms arising from alternative transcriptional start sites (Xiao et al., 1998) . We recently showed that several human ECs express RUNX2 in response to IGF-1 and extracellular matrix (ECM) binding and that a dominant-negative Runx expression vector inhibited EC migration and in vitro angiogenesis (Sun et al., 2001 ). In the current study, we report that aortic vascular sprouts and cultured EC express both a wild-type RUNX2 and a natural alternatively spliced isoform lacking exon 8 (RUNX2D8). To determine the biological function of these RUNX2 isoforms, we transfected ECs with expression vectors encoding either full-length RUNX2 or RUNX2D8. We show that these RUNX2 isoforms may regulate EC growth by modulating the TGFb 1 pathway through interactions with the promoter of the cyclin-dependent kinase inhibitor, p21 CIP1 , which controls cell cycle progression, DNA synthesis, and cell survival.
Results

Expression of the runx2 transcription factor in aortic vascular sprouts
Runx2 is a member of the family of Runx/AML transcription factors containing a Runt DNA-binding domain, a nuclear-localization signal, and several activation and repression domains (Westendorf and Hiebert, 1999) . Runx genes have been shown to be expressed during angiogenesis in mouse neovasculature after treatment with FGF-2 (Namba et al., 2000; Sun et al., 2001) . Rat aortic tissue was used to determine whether the Runx2 gene was also expressed during vascular sprouting in a physiologically relevant angiogenesis assay. This model recapitulates several steps in angiogenesis, such as expansion of the EC number, formation of cell-cell contacts, and subsequent growth arrest that are important in the formation of neovessels (Nicosia and Ottinetti, 1990) . Runx2 expression was analysed with Runx2-specific oligonucleotide primers corresponding to position 645 (upstream) and 1061 (downstream) in the C-terminal domain of the mouse and human Runx2 gene (Sun et al., 2001) . These primers do not detect Runx1 or Runx3 expression (data not shown). Rat aortic explants were cultured within fibrin gels (FGs) (Figure 1a ) under conditions that induce vascular sprouting (Nicosia and Tuszynski, 1994; Hiraoka et al., 1998) , expression of VEGF Nicosia and Tuszynski, 1994) , and the expression of ECM-degrading proteases such as urokinase plasminogen activator (uPA) (Rabbani, 1998) and membrane-type metalloproteinase (MT1-MMP) (Hiraoka et al., 1998) . A characteristic halo of vascular outgrowth was apparent 7 days after incubation of dissected rings at 371C (Figure 1a) . Expression of uPA was elevated 10-fold (normalized to cyclophilin (CP)) after 7-day culture in fibrin while MT1-MMP and VEGF increased by 7 days from undetectable levels ( Figure 1b , compare lanes 1 and 3). Expression of the expected 416 bp Runx2 product increased threefold (normalized to CP) in vascular sprouts relative to An alternatively spliced variant of RUNX2 lacking exon 8 is expressed in EC RT-PCR amplification of RUNX2 in human bone marrow endothelial cells (HBME) also generated two products, one of the expected 416 bp size and a second of 350 bp in size (Figure 2a , lane 1) as shown for aortic sprouts (Figure 1 ). To verify that the 416 and 350 bp PCR products were authentic RUNX2, bands corresponding to these products from HBME cells were sequenced (Figure 3 ). Sequence comparison showed that the 416 bp product was identical to the expected RUNX2 mRNA, while the 350 bp product was identical to RUNX2 except for a deletion of 66 bp near the 3 0 -end of the sequence (Figure 3a) . Comparison of the sequence of the smaller product with the published exon map (GenBank nucleotide sequence database (accession number NM_004348.1/GI:10863884) and the published intron/exon boundaries for RUNX2 (Geoffroy et al., 1998) revealed that the 350 bp PCR product corresponded to a RUNX2 mRNA with exon 8 deleted (designated RUNX2D8). Exon 8 encodes a peptide of 22 amino acids (Figure 3b ) that is unique to RUNX2 (Westendorf and Hiebert, 1999) .
Previous data had shown that serum withdrawal results in rapid loss of expression of RUNX2 and that ECM proteins mediate HBME differentiation, tube formation, and increased RUNX2 expression (Sun et al., 2001) . The alternatively spliced RUNX2 isoform, RUNX2D8, also displayed a short half-life of 3 h, relative to CP control in the absence of serum (Figure 2a) . Starved HBME cells were harvested and transferred to culture plates (PL) or to culture plates coated with two different ECM substrates: either FG or Matrigel (MG) in the presence (FBS) or absence (BSA) of serum (Figure 2b ). Culture on MG increased RUNX2 and RUNX2D8 mRNA expression about 1.8-and 1.6-fold, respectively, relative to PL and was independent of the presence of serum (Figure 2c , compare lanes 1, 2 and 3, 4). However, cells cultured on a FG coating showed 1.4-fold elevated RUNX2 levels relative to PL only in the presence of serum (Figure 2b , compare lanes 5 and 6). In other experiments, treatment of serum-starved cells with IGF-1 as before (Sun et al., 2001 ) stimulated comparable increases in expression of both RUNX2 isoforms, while RUNX2 isoforms in postconfluent cells were undetectable (data not shown).
RUNX2 DNA-binding activity and EC proliferation
RUNX2 is a DNA-binding transcription factor that interacts with the promoters of specific target genes (Ito, 1999; Zelzer et al., 2001) . To determine whether RUNX2 activity was involved in EC proliferation, endogenous RUNX2 DNA binding was measured by electrophoretic mobility-shift assay (EMSA) in proliferating (subconfluent) and growth-arrested (postconfluent) EC (Figure 4a, b) . Nuclear extracts from HBME Figure 2 RUNX2 expression and mRNA stability in human EC. (a) Reduced RUNX2 levels in the absence of serum. RNA was isolated as described in the Materials and methods section and expression determined with specific primers. CP was used to normalize the RT-PCR reactions. HBME cells were grown to subconfluence, incubated in the absence of FBS for 0-16 h (lanes 1-6) and RNA prepared as described in the Materials and methods. RT-PCR was performed using RUNX2-specific primers. Band intensities were calculated by densitometry normalized to CP control and show a t 1/2 ¼ 3 h (a, right panel). Data are representative of three separate experiments. (b) HBME cells that were incubated in the absence of FBS for 16 h were harvested with trypsin/EDTA and 5 Â 10 5 cells/ well were transferred to uncoated wells of a six-well plates (PL; lanes 1 and 2), wells coated with EHS matrix gel (MG; lanes 3 and 4) or wells coated with FG (lanes 5 and 6) in the presence of 10% FBS (lanes 1, 3, 5) or 0.1% BSA (lanes 2, 4, 6). Cells were incubated for 6 h and RNA was prepared for RT-PCR with RUNX2-specific primers Our previous data had shown that the angiogenic growth factor, IGF-1, increases RUNX2 mRNA and protein levels in HBME cells (Sun et al., 2001) . Consistent with a role for RUNX2 in EC proliferation, IGF-1-treated HBME cells also exhibited increased RUNX2 DNA-binding activity ( Figure 4c To determine whether RUNX2 or RUNX2D8 might regulate EC proliferation, vectors were prepared that would allow independent overexpression of each of these isoforms. Ectopic expression of RUNX2 and RUNX2D8 FLAG-tagged proteins was confirmed in transiently transfected HEK293 cells (Figure 4c , lanes 3 and 4). Nuclear extracts from HEK293 cells transfected with either RUNX2 (lane 3) or RUNX2D8 (lane 4) expressed similar levels of RUNX protein ( Figure 4c , panel 2) and exhibited similar RUNX2 DNA-binding activity (Figure 4c, panel 1) . Pooled, stably transfected HBME and bovine aortic endothelial cells (BAEC) also expressed ectopic RUNX2 by immunoblotting ( Figure 5a , lanes 2 and 3). Primary BAEC, which express low levels of endogenous Runx2, were used in subsequent growth assays. Confluent (synchronized) BAEC transfectants were harvested, replated in serumcontaining medium for 4, 24, 48, or 72 h and examined for growth rate using the MTT dye reduction assay. Over 3 days in culture, RUNX2 transfectants exhibited a greater increase in cell number (5.3-fold) than neo control (4.2-fold) or RUNX2D8 (3.6-fold) transfectants ( Figure 5b ). Analysis of DNA synthesis rates, determined using thymidine incorporation assays, were consistent with these results. RUNX2 transfectants exhibited twofold higher thymidine incorporation by 24 and 48 h in culture than neo or RUNX2D8 transfectants ( Figure 5c ). By 72 h, cells had reached confluence and became growth arrested. In addition, treatment of serum-starved RUNX2-transfected cells with serum for 3 or 6 h resulted in a dramatic increase in phosphorylated retinoblastoma (pRb) protein, indicative of progression into the cell cycle ( Figure 5d ). pRb levels in RUNX2D8 transfectants declined under the same conditions, while Neo transfectants showed a modest increase in pRb. These data suggest that RUNX2 is involved in the regulation of EC growth.
TGFb 1 -mediated growth inhibition and apoptosis
TGFb 1 functions as an angiogenic modulator by inhibiting the growth of EC and stimulating matrix protein synthesis and EC migration (Taipale and KeskiOja, 1997; Kalluri and Sukhatme, 2000) . To determine if BAEC expressing the RUNX2 isoforms retained their sensitivity to TGFb 1 growth modulation, postconfluent cells were harvested, replated, and cultured in the presence or absence of TGFb 1 for 48 h (Figure 6a ). Treatment of BAEC control (neo) transfectants with as little as 0.2 ng/ml TGFb 1 resulted in 50% inhibition of cell growth and 80% inhibition when cells were treated with 20 ng/ml TGFb 1 (Figure 6b ). RUNX2D8 transfectants treated with TGFb 1 responded similarly. However, treatment of RUNX2-transfected cells with 0.2 or 2.0 ng/ml TGFb 1 did not affect cell growth while treatment with 20 ng/ml inhibited growth by only 40%. Previous data from our laboratory had shown that expression of the dominant-negative Runt DNA- (Sun et al., 2001) . To determine whether RUNX2 expression could regulate EC migration in the presence of TGFb 1 , BAEC transfectants were spot cultured with a collagen overlay, treated with 10 ng/ml TGFb 1 , and sprouting from the central cell mass was examined ( Figure 6c , left panels). RUNX2-transfected cells showed a more robust sprouting response than NEO transfectants. RUNX2D8 transfected cells also exhibited a sprouting response, although the cells appeared more condensed and the nuclei more fragmented than NEO or RUNX2 transfectants ( Figure 6c , right panels).
Cell growth is a balance of positive (proliferation) and negative (apoptosis) events and RUNX2 transfectants continued to grow past confluence, while RUNX2D8-transfected cells did not ( Figure 5 ) with some evidence of apoptosis when treated with TGFb 1 (Figure 6c ). To determine whether RUNX2D8 expression contributed to apoptosis, postconfluent BAEC transfectants were harvested and replated in low serum in the presence of 2 ng/ml TGFb 1 . After 28 h, cells were fixed with formaldehyde and stained with DAPI to detect apoptotic nuclei (Figure 7a ). While neo and RUNX2 transfectants remained attached ( Figure 7b ) and exhibited low levels of apoptosis (Figure 7c ), RUNX2D8 transfectants appeared more loosely attached (note rounded cells in Figure 7b ) with a higher percentage of apoptotic cells (Figure 7c ). Nuclei were condensed and in many cases fragmented, consistent with apoptosis. In addition, more detached RUNX2D8 transfected cells were evident relative to neo or RUNX2 transfectants ( Figure 7d ) and increased cleavage of the caspase substrate, PARP, was observed in RUNX2D8 transfectants (Figure 7e ). By morphological criteria, approximately eightfold more RUNX2D8 transfectants were apoptotic than were neo or RUNX2 transfectants (Figure 7c ). The number of RUNX2D8 detached cells was 4-8-fold higher than neo or RUNX2 transfectants, respectively (Figure 7d ). However, RUNX2D8 transfectants did not exhibit any evidence of reduced proliferation in the absence of TGFb 1 (Figure 6 ). These results suggest that RUNX2, and more specifically its exon 8 domain, is involved in antagonizing TGFb 1 -mediated growth inhibition and in reducing TGFb 1 -mediated EC apoptosis.
Regulation of the promoter of the cyclin-dependent kinase inhibitor p21 cip1 by RUNX2 isoforms Inhibition of EC proliferation by TGFb 1 is mediated through activation of the p21 CIP1 promoter via a p53-independent mechanism (Datto et al., 1995) whereas RUNX2 is a strong transcriptional repressor of the p21 CIP1 promoter (Westendorf et al., 2002) . To determine whether deletion of the exon 8 domain would alter RUNX2 transcriptional regulation of the p21 CIP1 promoter, RUNX2D8 DNA binding and transactivation functions were evaluated. EMSA using the RUNXbinding element in the osteocalcin promoter (Figure 4) or a DNA precipitation assay with a biotin-labeled (Figure 8a , lanes 4 and 6) indicated no differences in relative DNA binding between RUNX2 and RUNX2D8 isoforms. Control mutant oligonucleotide (Figure 8a , lanes 5 and 7) did not interact with RUNX2 or RUNX2D8. In addition, RUNX2D8 was able to displace RUNX2 from the p21 CIP1 promoter target oligonucleotide (Figure 8a, lower panel) . Therefore, the ability of RUNX2D8 to repress the p21 CIP1 promoter was examined (Figure 8b-d) . Cotransfection of the p21 CIP1 -promoter-luciferase vector with RUNX2 in NIH3T3 cells resulted in threefold repression of endogenous p21 CIP1 promoter activity (Figure 8b ), while the same dose of RUNX2D8 or control plasmid (neo) did not inhibit basal activity. In cells treated with TGFb 1 (2 ng/ml), RUNX2 overexpression also repressed the p21 CIP1 promoter (Figure 8c ) by 2.2-fold, while neo and RUNX2D8 expression vectors did not. In the presence of Smad3 and constitutively active TGFb receptor (Alk5TD), RUNX2D8 was able to compete with RUNX2 to inhibit RUNX2-mediated repression of the p21 CIP1 promoter and to increase p21 CIP1 -promoterluciferase activity above baseline (Figure 8d ). Consistent with these data, RUNX2 could also inhibit the induction of p21 CIP1 protein in cells treated with doxorubicin, a chemotherapeutic agent that increases p21 CIP1 expression (Figure 8d, inset) . These results indicate that the antagonism of RUNX2 for TGFb 1 -induced growth inhibition in EC may be mediated, in part, by its ability to repress the cyclin-dependent kinase inhibitor p21 CIP1 and that the presence of exon 8 is important for this effect.
Discussion
We report the presence of an alternatively spliced Runx2 variant, Runx2D8, and wild-type Runx2 in EC and aortic vascular sprouts. The current study was designed to test the hypothesis that the RUNX2 isoforms play a Figure 5 Ectopic expression of RUNX2 isoforms and EC proliferation. (a) Protein expression in HEK293, HBME, or BAEC transfected with Flag-tagged vectors encoding RUNX2 isoforms was detected by Western blots using M2 (Flag-tag; for HBME and BAEC) or AML3 (RUNX2; for HBME) antibodies. The blots were reprobed with g-tubulin specific antibodies to verify equal loading. H-thymidine added to the medium for the final 1 h. Total cellular protein was determined from duplicate cultures and incorporation of label was normalized to cell protein content. n ¼ 3 for each experimental group (Po0.01 versus RUNX2D8 or neo at 24 or 48 h). (d) BAEC were transfected with 0.6 mg of the indicated cDNA and 6 ml lipofectin for 4 h in serum-free media. Serum (10%) was added for 18 h and the cells were serum starved for 48 h prior to treatment with 10% FBS for 0, 3, or 6 h as indicated. Western blotting with anti-Rb and g-tubulin control antibodies is shown RUNX2 in endothelial cells L Sun et al role in vascular remodeling by modulating the TGFb 1 growth inhibition pathway. The results indicate that RUNX2 expression and DNA-binding activity are associated with EC growth. Ectopic expression of RUNX2 increased EC proliferation, DNA synthesis, and phosphorylation of Rb, leading to attenuation of TGFb 1 -mediated growth inhibition. Conversely, RUNX2D8-expressing cells retained sensitivity to TGFb 1 . One possible mechanism that could account for these biological responses is the differential effect of these RUNX2 isoforms on the repression of the p21 CIP1 promoter. Whereas wild-type RUNX2 strongly repressed both basal and TGFb 1 -induced p21 CIP1 promoter activity, the alternatively spliced variant, RUNX2D8, was only a weak repressor and could compete with RUNX2 to inhibit repression of the p21 CIP1 promoter. A reasonable model that accounts for these observations is that the presence of exon 8 in full-length RUNX2 is permissive for cell proliferation and suppression of TGFb 1 -mediated growth inhibition through repression of the p21 CIP1 promoter while the absence of exon 8 sensitizes the cell to TGFb 1 -mediated apoptosis.
Alternatively spliced Runx2 and angiogenesis
Alternative splicing is an important mechanism to increase genetic diversity and may reflect tissue specificity, cellular stress conditions, the developmental state of the organism, or the pathological situation (Smith and Valcarcel, 2000; Sorek and Amitai, 2001 ). Many genes that control vascular cell function and angiogenesis are regulated by alternative splicing (Tischer et al., 1991; Takeichi et al., 1994; Nagata, 1996 The data represent the mean and standard deviations (bars) with asterisk indicating statistically significant differences between RUNX2 and neo or RUNX2D8 transfectants (Po0.01 at 0.2 ng/ml; Po0.05 at 2.0 and 20 ng/ml). (c) BAEC transfected with control (NEO), RUNX2, or RUNX2D8 were spot cultured in six-well plates and overlayered with collagen gel (3 mg/ml) in the presence of TGFb 1 (10 ng/ml) for 48 h (left panels). Higher magnification shows a representative cell from each well indicating DNA fragmentation in RUNX2D8 transfectants (right panel)
RUNX2 in endothelial cells
L Sun et al the expression of a particular splice variant may be regulated by the presence of cytokines or the cellular density. However, the mechanisms regulating alternative splicing have not been completely characterized (Kriventseva et al., 2003) . Runx2 levels increased during vascular sprouting from rat aorta and may be due to expression from mesenchymal myofibroblasts and/or EC (Hiraoka et al., 1998) . RUNX2 may be expressed during the early phases of angiogenesis (Kalluri and Sukhatme, 2000) when cell migration and proliferation occur to expand the number of ECs needed for new blood vessels. Expression may be low in quiescent and stable vessels (Namba et al., 2000; Sun et al., 2001) . These results are consistent with the presence of RUNX2 DNA-binding activity in proliferative, rather than quiescent EC in culture (Figure 4 ). Ectopic expression of RUNX2 supports these observations since RUNX2 overexpression increased cell growth, DNA synthesis, in vitro cell sprouting, and resistance to TGFb 1 in BAEC transfectants relative to control cells. EC within aortic sprouts secrete plasminogen activators and metalloproteinases, mediate degradation of the ECM during vascular sprouting, and respond to angiogenic cytokines such as VEGF (Nicosia and Ottinetti, 1990; Hiraoka et al., 1998; Hata-Sugi et al., 2002) . Previous observations from our laboratory showed that the expression of uPA and MT1-MMP was downregulated in EC transfected with dominant-negative Runt, which inhibited endogenous RUNX2 transcriptional activity (Sun et al., 2001 ). Since RUNX2 has been shown to activate the promoter of the VEGF gene (Zelzer et al., 2001) , the vascular sprouting data are consistent with coregulation of Runx2, VEGF, and protease genes. Expression of the endogenous alternatively spliced Runx2D8 variant increased in vascular sprouts from rat aorta while EC overexpressing RUNX2D8 exhibited enhanced cell migration, relatively lower rates of growth and DNA synthesis, and retained their sensitivity to TGFb 1 -mediated apoptosis. This is consistent with reports that EC vascular cell remodeling and apoptosis occur under conditions where blood vessels are expanding (Nor et al., 1999) or during atherosclerosis or restenosis, pathologic events that result in angiogenesis (Asahara et al., 1995) . The data also show that both RUNX2 and RUNX2D8 can stimulate cell migration when overexpressed in EC (Figure 6c ), consistent with increases in their endogenous expression in the primary tissue from rat aorta (Figure1).Therefore,onemechanismbywhichRUNX2D8 may regulate angiogenesis is by promoting the remodeling of new blood vessels.
TGFb 1 signaling and growth regulation
TGFb 1 is a multifunctional cytokine that either stimulates or inhibits angiogenesis (Pepper et al., 1990; Risau and Flamme, 1995) . TGFb 1 regulates matrix gene expression and migration in EC (Risau and Flamme, 1995) , inhibits EC growth through activation of the Smad signaling pathway (Laiho et al., 1990; Lyons and Moses, 1990; Newton et al., 1990; Koff et al., 1993; Massague and Wotton, 2000) , and induces EC apoptosis (Pollman et al., 1999) . RUNX2D8-expressing cells were sensitive to TGFb 1 treatment while RUNX2-expressing cells were relatively resistant. Other factors can also suppress the TGFb 1 growth inhibitory pathway. For example, HGF prevents the TGFb 1 inhibition of epithelial cell growth (Taipale and Keski-Oja, 1997) while FGF2 and TGFb 1 have opposing effects on EC plasminogen activator activity (Flaumenhaft et al., 1992) . In addition, the proto-oncogene c-myc can overcome the growth-inhibitory signaling of TGFb 1 (Alexandrow et al., 1995) and stimulate angiogenesis (Ngo et al., 2000) .
Other Runt-related genes have also been shown to interact with the TGFb 1 signaling pathway. Chromosomal translocations in leukemia give rise to a fusion protein consisting of AML1 (RUNX1) and the 8:21 corepressor (AML1-ETO). AML1-ETO functions as a dominant-negative factor by interacting with Smads, but fails to activate transcriptional responses upon TGFb 1 treatment (Jakubowiak et al., 2000) . The (Westendorf and Hiebert, 1999) . RUNX2 contains a QA domain at the Nterminus and exon 8 near the C-terminus, sequences that are missing in the RUNX1 and RUNX3 proteins (Westendorf and Hiebert, 1999) . Recently, the normal function of RUNX3 in gut epithelial cells was found to be the suppression of uncontrolled growth during development Ito and Miyazono, 2003) .
Cells from mice in which the Runx3 gene was inactivated failed to exhibit growth suppression or apoptosis in response to TGFb 1 . In addition, methylation of the RUNX3 promoter in human gastric carcinomas resulted in loss of sensitivity to TGFb 1 and increased survival. In our studies, transfection of the RUNX2D8 gene in EC resulted in the expression of a protein similar to RUNX3; both RUNX2D8 and RUNX3 (but not RUNX2) lack the exon 8 domain and mediate EC 
Transcriptional repression of the p21 CIP1 promoter
The p21 CIP1 cdk inhibitor regulates cell cycle progression, cell proliferation, and terminal differentiation in a variety of cells (Gartel and Tyner, 1999) , including EC (Yang et al., 1996; Roninson, 2002) . Unregulated expression of p21 CIP1 can lead to apoptosis (Smith, 2002) . Ectopic overexpression of p53 by adenoviral delivery to EC also increased p21 CIP1 expression and interfered with EC differentiation (Riccioni et al., 1998) . The c-myc proto-oncogene represses p21 CIP1 expression (Claassen and Hann, 2000) and Runx2 transgenic mice develop lymphomas in association with c-myc (Stewart et al., 1997; Vaillant et al., 1999) , suggesting that RUNX2 may regulate downstream targets much like c-myc . The related RUNX1 gene has been shown to act as a transcriptional activator of the cdk inhibitor p14 ARF , which induces cellular senescence in lymphoid cells (Linggi et al., 2002) , whereas AML1-ETO is a strong transcriptional repressor of the p14 ARF promoter and inactivates the p14 ARF tumor suppressor gene. In contrast, RUNX1 has been reported to repress the p21 CIP1 promoter (Lutterbach et al., 2000) . The C-terminus of RUNX2 contains motifs involved in transcriptional activation and repression (Figure 3b) . RUNX2, but not RUNX2D8, was a strong transcriptional repressor of the cdk inhibitor p21
CIP1
. Therefore, the absence of exon 8 appears to reduce the ability of RUNX2 to repress the p21 CIP1 promoter, suggesting that it is this domain within the C-terminus that may contribute to part of the RUNX2 transcriptional repression of the p21 CIP1 promoter. The histone deacetylase-6 corepressor (Westendorf et al., 2002) , which regulates p21 CIP1 promoter activity, interacts with RUNX2 within a region (residues 383-414) downstream of exon 8 (residues 332-354). Other corepressors, including mSin3A and TLE (Lutterbach et al., 2000) , which interact with the carboxy terminal region of RUNX2, may also be important in regulating p21 CIP1 promoter activity. Whether the deletion in exon 8 affects RUNX2 interaction with corepressors is currently under investigation.
In summary, RUNX2 attenuates the TGFb 1 -mediated growth inhibition of EC while the alternatively spliced variant RUNX2D8 promotes TGFb 1 -mediated EC apoptosis, suggesting that the mechanism of action of these two isoforms is distinct. These differential biological activities may be necessary for key events in angiogenesis that may be modulated through repression or activation of the p21 CIP1 promoter whose interaction with RUNX2 is influenced by the sequence encoded by exon 8 in the C-terminal domain of RUNX2.
Materials and methods
Reagents
Flag-M2 monoclonal, b-tubulin, and g-tubulin antibodies were obtained from Sigma (St Louis, MO, USA). The pRb antibody, which recognizes unphosphorylated and phosphorylated forms of Rb was from BD Biosciences (cat# 554136). Human TGFb 1 was from R&D Systems (Minneapolis, MN, USA) and the AML3/Cbfa1/RUNX2 antibody was from Oncogene Research Products (Cambridge, MA, USA). PARPspecific antibody was from Roche Diagnostics Corp. (Indianapolis, IN, USA). p21 CIP1 -specific antibody was obtained from Santa Cruz, Inc. (cat# sc-397). The RUNX2 cDNA clone (PEBP2aA) was obtained from Dr Yoshiaki Ito (Institute of Molecular and Cell Biology, Singapore) (Ogawa et al., 1993) , the p21 CIP1 -promoter-luciferase vector, WWP-Luc, (el-Deiry et al., 1993) from Dr Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA), the Smad3 expression vector from Drs Mark de Caestecker (Vanderbilt University) and Anne-Christine Poncelet (Northwestern University), and the constitutively active TGFb 1 receptor, Alk5TD, from Dr Mitsuyasu Kato (University of Tsukuba, Japan).
Cell culture HBME-1 (Lehr and Pienta, 1998), a gift from Dr Kenneth Pienta (University of Michigan Comprehensive Cancer Center) and BAEC, purchased from the Coriell Cell Repository (Camden, NJ, USA), were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS and antibiotics (Penicillin, Streptomycin, AmphotericinB) from Life Technologies Inc. (Rockville, MD, USA). BAEC were used at passage 8 or less. HBME-1 were used between passage 14 and 24. The human embryonic kidney 293 T cells were provided by Dr Robert Fenton, University of Maryland School of Medicine and cultured in DMEM containing 10% FBS.
Angiogenesis assays
Vascular sprouting was performed using aortas from 2-monthold Sprague-Dawley rats (Harlan, Indianapolis, IN, USA). Tissue was dissected and sections were implanted in FGs as described (Nicosia and Ottinetti, 1990; Nicosia and Tuszynski, 1994) . After culturing for 1 week at 371C, vascular sprouts were photographed and extracted with Trizol reagent (Invitrogen, Carlsbad, CA, USA) to isolate RNA. BAEC sprouting in vitro was determined by plating 5 Â 10 4 cells in 50 ml of complete medium (DMEM containing 10% FBS) for 6hr, removing the medium, and overlaying the attached cells ('spot culture') with a 3 mg/ml solution of neutralized type I collagen gel (Nicosia and Ottinetti, 1990; Nicosia and Tuszynski, 1994) . Complete medium was added to the cultures, cells were incubated for 3 days and sprouting from the central spots was documented with a video camera attached to a Zeiss microscopy and analysed with image analysis software (Oncor Image, Inc.).
RT-PCR
Expression of Runx2, the protease genes uPA and MT1-MMP, and the angiogenic factor, VEGF, was determined after RNA extraction using standard PCR methods and the following primers: as described (Sun et al., 2001) . For VEGF amplification, PCR was carried out using conditions as described previously (Burchardt et al., 1999) . Linear conditions were established by varying the levels of input cDNA. Relative inducible levels of expression were calculated after scanning densitometry using CP gene expression to normalize for loading. All PCR products were subcloned into the pGEM-T vector (Promega Corporation, Madison, WI, USA) and sequenced at the UMB Biopolymer Core Facility to verify gene identity.
Preparation of expression vectors
PCR subcloning with the FLAG-pCMV-Tag epitope mammalian expression vector pCMV-Tag2 (Stratagene, La Jolla, CA, USA) and the full-length PEBP2aA cDNA vector, pEFBoSaA1, (Ogawa et al., 1993) were used to construct the RUNX2 and RUNX2D8 expression plasmids (pCMV-Tag-RUNX2 and pCMV-Tag-RUNX2D8, respectively). PCR subcloning and the following RUNX2-specific primers were used. Full-length RUNX2: 5 0 -AGATCTGATGCGTATTCCTGTA GATCCG-3 0 (N-terminal with end of BglII site); 5 0 -CTCTC GAGTCAATATGGTCGCCAAACAG-3 0 (C-terminal with end of XhoI site). RUNX2D8: 5 0 -CAGTATGAGAGTAGGT GTCC-3 0 (N-terminal; BsgI 778) (722-741); 5 0 -AAGGGTCC ACTCTGGCTTTG-3 0 (C-terminal; XcmI 1255; 1248-1268). The full-length RUNX2 primers were used to amplify the full coding cDNA of RUNX2 with the pEF-BOSaA1 plasmid as template. The amplified fragment was purified and subcloned into pGEM-T vector (Promega Corporation, Madison, WI, USA). After sequencing to verify the RUNX2 gene, the insert was subcloned in-frame into the BglII and XhoI sites of the pCMV-Tag epitope mammalian expression vector pCMVTag2 (Stratagene, La Jolla, CA, USA). RUNX2D8 expression plasmid pCMV-Tag-RUNX2D8 was constructed using HBME cDNA as template and PCR amplification using the RUNX2D8 primers above. The resulting fragment of 486 bp was subcloned into the pGEM-T vector. Sequence analysis confirmed the identity of this short fragment to encompass the exon 8 deletion. The exon 8 deletion fragment was released from pGEM-T and subcloned into the BsgI and XcmI sites of the pCMV-Tag-RUNX2 vector.
Cell transfection
Transfection of HBME-1 or BAEC was carried out with Superfect transfection reagent according to the protocol provided by the manufacturer (Qiagen Inc., Valencia, CA, USA) or with Lipofectin (Gibco/BRL, Rockville, MD, USA) or Mirus TransIT LT1 (Mirus Corporation, Madison, WI, USA). Approximately 2 mg DNA were used for each 12 ml of transfection reagent. Two days after transfection, stable transfectants (polyclonal) were selected with 0.8 mg/ml (HBME) or 0.4 mg/ml (BAEC) of geneticin (Life Technologies Inc., Rockville, MD, USA) for 2 weeks. Western blotting was used to confirm the expression of RUNX2 and RUNX2D8 using the M2 anti-Flag-Tag antibodies as described below. For experimental results described in the text, four independent sets of selected polyclonal BAEC transfectants were used after fresh transfection with the RUNX plasmids, with essentially similar results from each set. Since BAEC are primary cells with a limited life-span, experiments were carried out within 2 weeks of selection. HEK293 cells were transfected using the calcium phosphate method (Gibco/BRL, Rockville, MD, USA).
DNA synthesis
Thymidine incorporation into acid-insoluble DNA was determined in BAEC cultured as described above. Cells were incubated for 48 h until confluent and subcultured into 96-well microtiter plates. A total of 1 Â 10 4 cells per well were seeded in triplicate. Following incubation at 371C for 4, 8, 24, 48 or 72 h, in a humidified atmosphere with 5% CO2, 3 H-thymidine (1 mCi/well) was added and the incubation was continued for an additional 1 h. Cells were washed with cold phosphate-buffered saline (PBS) and fixed in ice-cold 5% trichloroacetic acid to extract unincorporated radionucleotide. Acid-insoluble material from BAEC was dissolved in 100 ml of 1 N sodium hydroxide and neutralized with 100 ml of 1 N HCl.
3 H-thymidine incorporation was quantitated with a liquid scintillation counter (Beckman Model LS5801). Incorporation of label was normalized to cell protein content. Results are expressed as 3 H-thymidine dpm incorporated per microgram protein with n ¼ 3 for each experimental group.
Cell proliferation and apoptosis assays BAEC growth was quantitated using the MTT dye reduction assay (Wang and Passaniti, 1999) . Cells were cultured in 96-well plates (1 Â 10 4 cells/well) for 4, 24, 48 or 72 h at 371C in 100 ml DMEM containing 10% FBS. MTT dye (10 ml of a 5 mg/ml stock in PBS) was added per well. After incubation at 371C for 4 h, the crystalline formazan product was solubilized in 100 ml of 10% SDS þ 0.01 N HCl for 16 h and absorbance at 540 nm was measured with a BioRad Model 5450 plate reader. Mean and SD from the mean were calculated from n ¼ 4-6 per point. To measure the effect of TGFb 1 treatment on BAEC proliferation, postconfluent cells were harvested and 1 Â 10 5 cells were replated per well of a six-well plate. Cells were cultured in growth media in the presence or absence of TGFb 1 (0.2, 2.0, 20 ng/ml) for 48 h and fixed with 3.7% PBS-buffered formaldehyde. DAPI stain (1 mg/ml; Molecular Probes, Inc., Eugene, OR, USA) was added to formaldehyde-fixed cells to visualize nuclei and representative fields from each well were photographed. Cell number was calculated by counting individual nuclei from at least three fields of each well. To measure the effect of TGFb 1 on BAEC apoptosis, postconfluent cells were harvested and replated in 0.2%FBS in the presence of 2 ng/ ml TGFb 1 in six-well plates as described for proliferation. After 28 h, cells were fixed with formaldehyde and stained with DAPI to detect apoptotic nuclei. Apoptosis was quantitated by counting the number of apoptotic nuclei (using morphological parameters of nuclear condensation and fragmentation). Detached cells were counted by collecting the media from each well and adding 100 ml of each supernatant to glass slides, overlayed with coverslips. To measure cleavage of the caspase 3 substrate, PARP, cells were lysed in SDS-PAGE buffer, proteins were resolved on SDS-PAGE and the 116 kDa/80 kDa PARP proteins were detected by Western blotting.
Protein extraction and immunoblot
For whole cell lysate preparation, 1 Â 10 7 cells were harvested and lysed in 1 ml of lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM DTT, 4 mM EDTA, 50 mM NaF, 0.1 mM Na3VO 4 , 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml pepstatin A, 10 mg/ml chymostatin, 1% NP-40 and 0.1% Triton X-100). After incubation at 41C for 15 min, the lysate was cleared by micro-centrifugation at 10 000 g for 10 min at 41C. The protein concentration in each sample was determined with the BioRad Bradford assay. Equal amounts of protein (15 mg) were denatured by heating to 951C in Laemmli sample buffer and were resolved by 12% SDS-PAGE, followed by transfer to PVDF membranes. The membranes were probed with the indicated antibodies and detected using an ECL system per manufacturer's recommendation (Amersham Pharmacia Biotech, Buckinghamshire, England). g-tubulin was used as a loading control and was measured by reprobing the stripped membranes with anti-g-tubulin antibody (Sigma, St Louis, MO, USA). In some cases, immunoprecipitated protein (M2-Flag antibody) from RIPA lysates was resolved on SDS-PAGE prior to Western blotting.
EMSA and DNA precipitation
Nuclear extracts were prepared by hypotonic lysis of cells and extraction of nuclear proteins with high salt buffer (Wang and Passaniti, 1999) . Labeled double-stranded oligonucleotide containing the consensus RUNX-binding promoter element TGTGGTT was mixed with nuclear extracts and binding complexes were resolved on 6% TBE PAGE. Specific RUNX2 antibody (0-0.4 mg) and nonspecific, control (g-tubulin) antibody were used to verify the presence of RUNX2 in the shifted complex. Cold 100-fold excess specific (RUNX-binding site) or 100-fold excess nonspecific (Stat-binding site) oligonucleotides were used as controls. For DNA precipitation assays (DNAP), wild type or mutant double-stranded oligonucleotides containing a RUNX-binding site from the p21 CIP1 promoter were incubated with nuclear extracts expressing Flag.Tag.RUNX2 or Flag.Tag.RUNX2D8 and specific complexes were isolated with streptavidin-agarose beads.
Luciferase assays
The Dual Luciferase kit from Promega (Madison, WI, USA) was used to quantitate repression or activation of the p21-promoter by RUNX2 isoforms or TGFb 1 , respectively. Briefly, NIH3T3 cells were plated in six-well plates at a density of 1.2 Â 10 5 cells/well. After 24 h, the cells were transfected with appropriate plasmids (neo control, RUNX2, or RUNX2D8, p21-promoter-luciferase, Alk5TD, Smad3) and using the TransIT-LT1 reagent (Mirus Corporation, Madison, WI, USA) as suggested by the manufacturer. The TK-Renilla vector was used to normalize luciferase units in each transfection. Cells were lysed 48 h after transfection with passive lysis buffer supplied in the Dual Luciferase kit. The lysates were then analysed following the Dual Luciferase standard protocol and using the Turner Design Model TD-20/ 20 Luminometer.
Statistical analysis
Data was expressed as mean7s.d. Statistical differences for cell growth, DNA synthesis, apoptosis, and luciferase measurements were analysed with Student's t-test.
Abbreviations EC, endothelial cell; TGFb 1 , transforming growth factor-b; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; IGF-1, insulin-like growth factor-1; RHD, Runt homology domain; uPA, urokinase plasminogen activator; NF-kB, nuclear factor-kB; CP, cyclophilin; MT1-MMP, membrane-type metalloproteinase-1; EMSA, electrophoretic mobility-shift assay; BAEC, bovine aortic endothelial cells; HBME, human bone marrow endothelial cells. RUNX2 indicates the human gene whereas Runx2 indicates the mouse gene. In reference to general cases, Runx is used.
